We are excited to have you join us on Wednesday, November 24, 2021 at 7:00–8:00pm ET.

Join the discussion with:

Lorne Zinman  
MD, M.Sc., FRCPC  
Director, ALS/Neuromuscular Clinic  
Associate Professor of Neurology, University of Toronto  
Sunnybrook Health Sciences Centre

Program overview

ALS remains a devastating and terminal neurodegenerative disease with 80% of patients dying within 2–5 years of diagnosis. However, a number of key advancements have led to the development of new diagnostic criteria, a novel therapeutic to slow disease progression, and a research pipeline of innovative and promising therapeutic strategies and targets.

Healthcare professionals attending this event will explore breaking updates in ALS that are of high interest to neurologists practising in Canada. Such topics will include an outline of novel diagnostic criteria, exciting clinical trial activity with Canadian participation, the newly published Canadian Best Practice Recommendations, and real-world evidence initiatives. Innovative new methods for accessing the CNS through MRI-Guided Focused Ultrasound developed at the University of Toronto will also be discussed. Given the important roles early diagnosis and referral to academic ALS centres play in optimizing patient care and maximizing research trial eligibility, challenging case scenarios will explore red flags and timing for referrals based on the most up-to-date information available with the end goal of improving overall ALS patient care.

By the end of this course participants will be able to:

- Recognize the important role community neurologists play in early ALS diagnosis and referral to optimize care.
- Understand the potential impact of current research advances on the road to a cure.

Register today!

You can also scan the QR code to register!

This event will take place over Zoom. However, you will not need to download Zoom to view if you select “Join from your browser.”

This Webinar is an unaccredited group learning approved by the Canadian Neurological Sciences Federation. The program was developed by the Canadian Neurological Sciences Federation and the faculty and was planned to achieve scientific integrity, objectivity, and balance. This Webinar was supported by Mitsubishi Tanabe Pharma Canada, who provided an unrestricted grant and in-kind support.